Clinical Trials Logo

Clinical Trial Summary

The objectives of this study are to explore the effect of adalimumab on the fecal Calprotectin level of Ulcerative Colitis (UC) patients and the correlation with their general well-being (QoL), work ability and disease activity.


Clinical Trial Description

This is a non-interventional, observational study in which Humira (adalimumab) is prescribed in the usual manner in accordance with the terms of the local marketing authorization with regards to dose, population and indication. The assignment of the patient to a Humira containing regimen has to be decided in advance and has to be current practice. The prescription of Humira is clearly separated from the decision to include the participant in this study. ;


Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


NCT number NCT02092389
Study type Observational
Source AbbVie
Contact
Status Terminated
Phase N/A
Start date July 2014
Completion date March 2017

See also
  Status Clinical Trial Phase
Withdrawn NCT03627052 - A Study to Evaluate the Safety and Efficacy of Itacitinib in Moderate to Severe Ulcerative Colitis Phase 2
Recruiting NCT05486104 - Phase II Study of Hemay005 in Patients With Active Ulcerative Colitis Phase 2
Recruiting NCT04879966 - A Cohort Study Comparing IFX to CS for Moderate to Severe UC
Completed NCT04700449 - A Study Assessing the Efficacy and Safety of CBP-307 in Subjects With Moderate to Severe Ulcerative Colitis (UC) Phase 2
Completed NCT04090411 - A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Severe Ulcerative Colitis Phase 2